Osiris Therapeutics, Inc.
OSIRIS THERAPEUTICS, INC. (Form: 25-NSE, Received: 04/28/2017 09:27:35)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-32966

Issuer:  OSIRIS THERAPEUTICS, INC.
Exchange:  NASDAQ Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address:  7015 Albert Einstein Drive
Columbia,
MARYLAND
21046
Telephone number:  443 545-1819
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Stock
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
o  17 CFR 240.12d2-2(a)(1)
o  17 CFR 240.12d2-2(a)(2)
o  17 CFR 240.12d2-2(a)(3)
o  17 CFR 240.12d2-2(a)(4)
x   Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
o   Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements for the Securities Exchange Act of 1934, NASDAQ Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2017-04-28 By Amy Horton Hearings Advisor
Date Name Title
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Delisting Determination,The Nasdaq Stock Market, LLC, April 28, 2017, Osiris Therapeudics, Inc. The Nasdaq Stock Market, Inc. (the Exchange) has determined to remove from listing the common stock of Osiris Therapeudics, Inc. (the Company), effective at the opening of the trading session on May 8, 2017. Based on review of information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Listing Rule 5250(c)(1).
The Company was notified of the Staffs determination on September 14, 2016. The Company appealed the determination to a Hearing Panel. Upon review of the information provided by the Company, the Panel issued a decision dated December 1, 2016, granting the Company continued listing pursuant to an exception that included several milestones that the Company was required to meet, towards the toal of regaining compliance with Listing Rules 5250(c)(1) and 5620(a). However, the Company was
unable to meet the exception milestones as required. On March 10, 2017, the Panel issued a final delisting determination and notified the Company that trading in the Companys securities would be suspended on March 14, 2017. The Company did not request a review of the Panels decision by the Nasdaq Listing and Hearing Review Council. The Listing Council did not call the matter for review. The Panels Determination to delist the Company became final on April 24, 2017.